月曜日

• 18:00～ 研究カンファレンス（スタッフ、医員、大学院生）
  前週の研究の進捗状況について報告、議論します。

木曜日

• 7:45～8:30 モーニングカンファレンス（スタッフ、医員、大学院生）
• 9:00～12:00 呼吸器内科臨床カンファレンス
  研修医が入院患者全員についての胸部X線、CTを提示し、プレゼンテーションします。

呼吸器疾患は肺癌・肺感染症・COPD・喘息・間質性肺疾患・肺循環障害・呼吸不全・睡眠時無呼吸症候群など多岐にわたり、また、診療において呼吸器外科、放射線科、病理部との連携が必須です。

入院患者の多くを占める肺癌、間質性肺疾患、肺感染症各診療グループによる検討会や他科との合同カンファレンスに参加することで、各研修医は受け持っている症例の診療方針について検討を深めることができます。

火曜日

• 16:30～ 肺感染症カンファレンス
• 18:00～ 間質性肺疾患カンファレンス

水曜日

• 18:00～ 肺癌カンファレンス

木曜日

• 17:00～ 呼吸器内科・外科・放射線科合同カンファレンス
• 18:00～ COPDグループミーティング(毎週)

当教室は、旧京都大学胸部疾患研究所附属病院において、感染症科、呼吸器内科、理学呼吸器科の三科に分かれていたものが、平成１3年統合され、発足いたしました。
下記にあげますような、幅広い呼吸器疾患の臨床及び研究に日夜励んでおります。

• 呼吸不全・睡眠呼吸障害
• 間質性肺疾患
• COPD
• 喘息・慢性咳嗽
• 感染症
• 肺がん

各研究グループの英文論文を掲載させていただきます。

• 呼吸不全、睡眠呼吸障害

  • 詳しくはこちらをご覧下さい。

• 間質性肺疾患

  • 2013年

    1. Handa T, Nakatsue T, Baba M, Takada T, Nakata K, Ishii H. Clinical Features of three Cases with Pulmonary Alveolar Proteinosis Secondary to Myelodysplastic Syndrome developed during the course of Behçet’s Disease. Respir Investig 2013 in press.
    2. Aihara K, Handa T, Oga T, Watanabe K, Tanizawa K, Ikezoe K, Taguchi Y, Sato H, Chin K, Nagai S, Narumiya S, Wells AU, Mishima M. Clinical relevance of plasma prostaglandin f2α metabolite concentrations in patients with idiopathic pulmonary fibrosis.　PLoS One. 2013 Jun 11;8(6):e66017.
    3. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Aihara K, Ikezoe K, Watanabe K, Taguchi Y, Hatta K, Oga T, Chin K, Nagai S,Mimori T, Mishima M. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med. 2013; 107:745-752.
    4. Tanizawa K, Handa T, Nagai S, Sato H, Yamada R, Ito I, Kubo T, Ito Y, Watanabe K, Aihara K, Ikezoe K, Mishima M, Izumi T. Interferon regulatory factor 5 polymorphisms in sarcoidosis. Mod Rheumatol 2013.
    5. Aihara K, Handa T, Nagai S, Tanizawa K, Ikezoe K, Watanabe K, Chihara Y, Harada Y, Yoshimura C, Oga T, Ozasa N, Uno K, Chin K, Mishima M. Impaired endothelium-dependent vasodilator response in patients with pulmonary fibrosis. Respir Med 2013; 107:269-275.
       

       2012年

    6. Baughman RP, Drent M, Culver DA, Grutters JC, Handa T, Humbert M, Judson MA, Lower EE, Mana J, Pereira CA, Prasse A, Sulica R,Valyere D, Vucinic V, Wells AU. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012; 29:90-98.
    7. Hasegawa K, Ohno S, Takada M, Ogino H, Shiotsu S, Takumi C, Hiraoka N, Handa T, Nagai S. Sarcoidosis complicated with major pulmonary artery obstruction and stenosis. Intern Med. 2012; 51:2775-2780.
       

       2011年

    8. Tanizawa K, Handa T, Nagai S, Ito I, Kubo T, Ito Y, Watanabe K, Aihara K, Mishima M, Izumi T. A CD40 single-nucleotide polymorphism affects the lymphocyte profiles in the bronchoalveolar lavage of Japanese patients with sarcoidosis.　Tissue Antigens 2011; 78:442-445.
    9. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, Aihara K, Oga T, Chin K, Nagai S, Mimori T, Mishima M. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 2011; 105:1380-1387.
    10. Aihara K, Handa T, Nagai S, Tanizawa K, Watanabe K, Harada Y, Chihara Y, Hitomi T, Oga T, Tsuboi T, Chin K, Mishima M. Efficacy of blood-patch pleurodesis for secondary spontaneous pneumothorax in interstitial lung disease. Intern Med 2011; 50:1157-1162.
    11. Tanizawa K, Handa T, Nagai S, Oga T, Kubo T, Ito Y, Watanabe K, Aihara K, Chin K, Mishima M, Izumi T. Validation of the Japanese version of the Sarcoidosis Health Questionnaire: A cross-sectional study. Health Qual Life Outcomes 2011; 9:34.
    12. Watanabe K, Handa T, Tanizawa K, Hosono Y, Taguchi Y, Noma S, Kobashi Y, Kubo T, Aihara K, Chin K, Nagai S, Mimori T, Mishima M. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med 2011; 105:1238-1247.
        

        2010年

    13. Tomii K, Tachikawa R, Chin K, Murase K, Handa T, Mishima M, Ishihara K. Role of non-invasive ventilation in managing life-threatening acute exacerbation of interstitial pneumonia. Intern Med 2010; 49:1341-1347.
    14. Handa T, Nagai S, Ueda S, Chin K, Ito Y, Watanabe K, Tanizawa K, Tamaya M, Mishima M, Izumi T.　Significance of plasma NT-proBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis.　Sarcoidosis Vasc Diffuse Lung Dis 2010; 27:27-35.

    a

    15. Tanizawa K, Handa T, Nagai S, Ito Y, Watanabe K, Aihara K, Izumi T, Mishima M.　CD24 gene exon 2 dimorphism does not affect disease susceptibility in Japanese sarcoidosis patients.　Sarcoidosis Vasc Diffuse Lung Dis 2010; 27: 64-69.

        2009年

    16. Handa T, Nagai S, Hirai T, Chin K, Kubo T, Oga T, Niimi A, Matsumoto H, Ito Y, Takahashi K, Watanabe K, Izumi T, Mishima M. Computed tomography analysis of airway dimensions and lung density in patients with sarcoidosis. Respiration 2009; 77:273-281.
    17. Handa T, Nagai S, Kitaichi M, Chin K, Ito Y, Oga T, Takahashi K, Watanabe K, Mishima M, Izumi T Long-term complications and prognosis of chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26:24-31.
        

        2008年

    18. Nagai S, Handa T, Ito Y, Ohta K, Tamaya M, Izumi T. Outcome of sarcoidosis. Clin Chest Med 2008; 29: 565-574.
    19. Nagai S, Handa T, Kim D. Pharmacotherapy in patients with idiopathic pulmonary fibrosis. Expert Opin Pharmacother 2008; 9: 1909-1925.
        

        2007年

    20. Nagai S, Handa T, Ito Y, Takeuchi M, Izumi T. Bronchoalveolar lavage in idiopathic interstitial lung diseases.　Semin Respir Crit Care Med 2007; 28: 496-503.
    21. Hamada K, Nagai S, Tanaka S, Handa T, Shigematsu M, Nagao T, Mishima M, Kitaichi M, Izumi T. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131:650-656.
    22. Handa T, Nagai S, Miki S, Ueda S, Yukawa N, Fushimi Y, Ito Y, Ohta K, Mimori T, Mishima M, Izumi T. Incidence of pulmonary hypertension and its clinical relevance in patients with interstitial pneumonias: comparison between idiopathic and collagen vascular disease associated interstitial pneumonias. Intern Med 2007; 46:831-837.
    23. Sato H, Nagai S, du Bois RM, Handa T, Suginoshita Y, Ohta K, Welsh KI, Izumi T. HLA-DQB1 0602 allele is associated with splenomegaly in Japanese sarcoidosis. J Intern Med 2007; 262:449-457.
        

        2006年

    24. Handa T, Nagai S, Miki S, Fushimi Y, Ohta K, Mishima M, Izumi T. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129:1246-1252.
    25. Handa T, Nagai S, Fushimi Y, Miki S, Ohta K, Niimi A, Mishima M, Izumi T. Clinical and radiographic indices associated with airflow limitation in patients with sarcoidosis. Chest 2006; 130:1851-1856.
        

        2005年

    26. Handa T, Nagai S, Ito I, Tabuena R, Shigematsu M, Hamada K, Kitaichi M, Izumi T, Aoyama T, Toguchida J, Mishima M. Polymorphisms of B7 (CD80 and CD86) genes do not affect disease susceptibility to sarcoidosis. Respiration 2005; 72:243-248.
    27. Handa T, Nagai S, Kawabata D, Nagao T, Takemura M, Kitaichi M, Izumi T, Mimori T, Mishima M. Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med 2005; 44:319-325.
    28. Handa T, Nagai S, Ito I, Shigematsu M, Hamada K, Kitaichi M, Ohta K, Izumi T, Mishima M. Multiple bone fractures found in a young sarcoidosis patient with long stable disease. Intern Med 2005; 44:1269-1275.
    29. Handa T, Nagai S, Shigematsu M, Tabuena RP, Takeuchi M, Mikuniya T, Hamada K, Izumi T, Mishima M. Patient characteristics and clinical features of Japanese sarcoidosis patients with low bronchoalveolar lavage CD4/CD8 ratios. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:154-160.
    30. Ito I, Nagai S, Handa T, Muro S, Hirai T, Tsukino M, Mishima M. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 2005; 172: 1378-1382.
    31. Tabuena RP, Nagai S, Tsutsumi T, Handa T, Minoru T, Mikuniya T, Shigematsu M, Hamada K, Izumi T, Mishima M. Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese Patients. Respiration 2005; 72: 490-498.
    32. Ito I, Nagai S, Kitaichi M, Nicholson AG, Johkoh T, Noma S, Kim DS, Handa T, Izumi T, Mishima M. Pulmonary manifestations of primary Sjogren’s syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005; 171:632-638.
        

        2004年

    33. Tabuena RP, Nagai S, Handa T, Shigematsu M, Hamada K, Ito I, Izumi T, Mishima M, Sharma OP. Diabetes insipidus from neurosarcoidosis: long-term follow-up for more than eight years. Intern Med 2004 ; 43: 960-966.
    34. Nagai S, Handa T, Tabuena R, Kitaichi M, Izumi T. Nonspecific interstitial pneumonia: a real clinical entity? Clin Chest Med 2004; 25: 705-715.
        

        2003年

    35. Handa T, Nagai S, Hamada K, Ito I, Hoshino Y, Shigematsu M, Izumi T, Mishima M. Sarcoidosis with bilateral epididymal and testicular lesions. Intern Med 2003; 42: 92-97.
    36. Handa T, Ono T, Watanabe H, Takeda T, Muso E, Kita T.　Glomerulonephritis induced by methicillin-sensitive Staphylococcus aureus infection.　Clin Exp Nephrol 2003; 7:247-249.
    37. Handa T, Nagai S, Ito I, Shigematsu M, Hamada K, Kitaichi M, Izumi T, Mishima M. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) exon 1 polymorphism affects lymphocyte profiles in bronchoalveolar lavage of patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 190-196.

• COPD

  • [1-58]

    2014年

    1. Tabara Y, Muro S, Takahashi Y, Setoh K, Kawaguchi T, Terao C, Kosugi S, Sekine
       A, Yamada R, Nakayama T, Mishima M, Matsuda F; Nagahama Study Group. Airflow
       limitation in smokers is associated with arterial stiffness: the Nagahama Study.
       Atherosclerosis. 2014 Jan;232(1):59-64.
    2. Marumo S, Hoshino Y, Kiyokawa H, Tanabe N, Sato A, Ogawa E, Muro S, Hirai T,
       Mishima M. p38 mitogen-activated protein kinase determines the susceptibility to
       cigarette smoke-induced emphysema in mice. BMC Pulm Med. 2014 May 7;14:79. doi:
       10.1186/1471-2466-14-79.
    3. Kinose D, Ogawa E, Kudo M, Marumo S, Kiyokawa H, Hoshino Y, Hirai T, Chin K,
       Muro S, Mishima M. Association of COPD exacerbation frequency with gene
       expression of pattern recognition receptors in inflammatory cells in induced
       sputum. Clin Respir J. 2014 Jun 5.
    4. Tanimura K, Hirai T, Sato S, Hasegawa K, Muro S, Kurosawa H, Mishima M.
       Comparison of two devices for respiratory impedance measurement using a forced
       oscillation technique: basic study using phantom models. J Physiol Sci. 2014
       Sep;64(5):377-82.
    5. 室　繁郎
       【COPD治療の新時代　21世紀の「社会的」生活習慣病】 COPDの早期診断,治療の枠組み,急性増悪の対応　新薬乱立の前に知っておくべきこと
       内科(0022-1961)113巻2号 Page217-225(2014.02)
    6. 室　繁郎
       【喘息・COPD患者への吸入指導】 COPDの診断と治療　ガイドラインをふまえて
       薬事(0016-5980)56巻3号 Page327-332(2014.03)
    7. 佐藤 篤靖, 室 繁郎
       【COPDを改めて問う】 COPDにおける併存症　気流閉塞、肺気腫いずれに関与しているのか
       THE LUNG-perspectives(0919-5742)22巻2号 Page171-174(2014.05)
    8. 室　繁郎
       【COPDの最新情報】 (Topics 5)併存症・合併症のインパクトとその対策
       日本呼吸器学会誌(2186-5876)3巻3号 Page344-351(2014.05)
    9. 佐藤 晋, 室 繁郎
       【疾患と運動時低酸素血症】 COPDと運動時低酸素血症
       呼吸と循環(0452-3458)62巻6号 Page545-551(2014.06)
    10. 佐藤 晋, 室 繁郎, 三嶋 理晃
        【高齢者の呼吸器疾患-若年・高齢者発症との違い-】 COPD　若年発症COPDと高齢者COPDについて
        日本胸部臨床(0385-3667)73巻8号 Page876-885(2014.08)
    11. 佐藤 晋, 室 繁郎
        【全身成人病としてのCOPD】 COPDの呼吸機能
        成人病と生活習慣病(1347-0418)44巻9号 Page1013-1018(2014.09)
    12. 室　繁郎
        呼吸器疾患診療を支える臨床検査 COPD診療における呼吸機能とCT画像の役割
        臨床病理(0047-1860)62巻12号 Page1212-1217(2014.12)

        2013年

    13. Tabara Y, Takahashi Y, Setoh K, Muro S, Kawaguchi T, Terao C, Kosugi S, Sekine A, Yamada R, Mishima M, Nakayama T, Matsuda F; on behalf of the Nagahama Study Group. Increased aortic wave reflection and smaller pulse pressure amplification in smokers and passive smokers confirmed by urinary cotinine levels: The Nagahama Study. Int J Cardiol. 2013 Apr 8. doi:pii: S0167-5273(13)00447-6. 10.1016/j.ijcard.2013.03.028. [Epub ahead of print]
    14. Oguma T, Hirai T, Niimi A, Matsumoto H, Muro S, Shigematsu M, Nishimura T, Kubo Y, Mishima M. Limitations of airway dimension measurement on images obtained using multi-detector row computed tomography. PLoS One. 2013 Oct 8;8(10):e76381. doi: 10.1371/journal.pone.0076381.
    15. Tanabe N, Hoshino Y, Marumo S, Kiyokawa H, Sato S, Kinose D, Uno K, Muro S, Hirai T, Yodoi J, Mishima M. Thioredoxin-1 Protects against Neutrophilic Inflammation and Emphysema Progression in a Mouse Model of Chronic Obstructive Pulmonary Disease Exacerbation. PLoS One. 2013 Nov 11;8(11):e79016. doi: 10.1371/journal.pone.0079016.
    16. Tabara Y, Muro S, Takahashi Y, Setoh K, Kawaguchi T, Terao C, Kosugi S, Sekine A, Yamada R, Nakayama T, Mishima M, Matsuda F; Nagahama Study Group. Airflow limitation in smokers is associated with arterial stiffness: The Nagahama Study Atherosclerosis. 2014 Jan;232(1):59-64. doi: 10.1016/j.atherosclerosis.2013.10.020. Epub 2013 Nov 1.
        

        2012年

    17. Tanabe N, Muro S, Sato S, Tanaka S, Oguma T, Kiyokawa H, Takahashi T, Kinose
        D, Hoshino Y, Kubo T, Hirai T, Mishima M. Longitudinal study of spatially heterogeneous emphysema progression in current smokers with chronic obstructive
        pulmonary disease. PLoS One. 2012;7(9):e44993. doi: 10.1371/journal.pone.0044993.
        Epub 2012 Sep 18.
    18. Suzuki M, Muro S, Ando Y, Omori T, Shiota T, Endo K, Sato S, Aihara K,
        Matsumoto M, Suzuki S, Itotani R, Ishitoko M, Hara Y, Takemura M, Ueda T, Kagioka
        H, Hirabayashi M, Fukui M, Mishima M. A randomized, placebo-controlled trial of
        acupuncture in patients with chronic obstructive pulmonary disease (COPD): the
        COPD-acupuncture trial (CAT). Arch Intern Med. 2012 Jun 11;172(11):878-86.
    19. Takahashi T, Muro S, Tanabe N, Terada K, Kiyokawa H, Sato S, Hoshino Y, Ogawa
        E, Uno K, Naruishi K, Takashiba S, Mishima M. Relationship between
        periodontitis-related antibody and frequent exacerbations in chronic obstructive
        pulmonary disease. PLoS One. 2012;7(7):e40570. Epub 2012 Jul 11.
    20. Tanabe N, Muro S, Fuseya Y, Sato S, Oguma T, Kiyokawa H, Takahashi T, Kinose
        D, Hoshino Y, Kubo T, Hirai T, Mishima M. Peri-diaphragmatic lung volume assessed
        by computed tomography correlates with quality of life in patients with chronic
        obstructive pulmonary disease. Respirology. 2012 Oct;17(7):1137-43. doi:
        10.1111/j.1440-1843.2012.02221.x.
    21. Tanabe N, Muro S, Tanaka S, Sato S, Oguma T, Kiyokawa H, Takahashi T, Kinose
        D, Hoshino Y, Kubo T, Ogawa E, Hirai T, Mishima M. Emphysema distribution and
        annual changes in pulmonary function in male patients with chronic obstructive
        pulmonary disease. Respir Res. 2012 Apr 18;13:31. doi: 10.1186/1465-9921-13-31.
    22. Tanabe N, Muro S, Oguma T, Sato S, Kiyokawa H, Takahashi T, Kudo M, Kinose D,
        Kubo T, Hoshino Y, Ogawa E, Hirai T, Mishima M. Computed tomography assessment of pharmacological lung volume reduction induced by bronchodilators in COPD. COPD.
        2012 Aug;9(4):401-8. Epub 2012 Apr 18.
    23. Kudo M, Ogawa E, Kinose D, Haruna A, Takahashi T, Tanabe N, Marumo S, Hoshino
        Y, Hirai T, Sakai H, Muro S, Date H, Mishima M. Oxidative stress induced
        interleukin-32 mRNA expression in human bronchial epithelial cells. Respir Res.
        2012 Mar 14;13:19.
    24. Kiyokawa H, Muro S, Oguma T, Sato S, Tanabe N, Takahashi T, Kudo M, Kinose D,
        Kondoh H, Kubo T, Hoshino Y, Ogawa E, Hirai T, Mishima M. Impact of COPD
        exacerbations on osteoporosis assessed by chest CT scan. COPD. 2012 Jun;9(3):235-42. Epub 2012 Feb 23.
    25. Ito Y, Hirai T, Maekawa K, Fujita K, Imai S, Tatsumi S, Handa T, Matsumoto H,
        Muro S, Niimi A, Mishima M. Predictors of 5-year mortality in pulmonary
        Mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis.
        2012;16(3):408-14. Epub 2012 Jan 5.

        2011年

    26. Matsumoto H, Hirata Y, Otsuka K, Iwata T, Inazumi A, Niimi A, Ito I, Ogawa E,
        Muro S, Sakai H, Chin K, Oku Y, Mishima M. Interleukin-13 enhanced Ca2+
        oscillations in airway smooth muscle cells. Cytokine. 2012 Jan;57(1):19-24. Epub
        2011 Nov 9.
    27. Hoshino Y, Muro S, Mishima M. [Novel therapeutics for COPD]. Nihon Rinsho.
        2011 Oct;69(10):1826-30. Review. Japanese.
    28. Otsuka K, Matsumoto H, Niimi A, Muro S, Ito I, Takeda T, Terada K, Yamaguchi
        M, Matsuoka H, Jinnai M, Oguma T, Nakaji H, Inoue H, Tajiri T, Iwata T, Chin K,
        Mishima M. Sputum YKL-40 levels and pathophysiology of asthma and chronic
        obstructive pulmonary disease. Respiration. 2012;83(6):507-19. doi:
        10.1159/000330840. Epub 2011 Sep 27.
    29. Kinose D, Ogawa E, Hirota T, Ito I, Kudo M, Haruna A, Marumo S, Hoshino Y,
        Muro S, Hirai T, Sakai H, Date H, Tamari M, Mishima M. A NOD2 gene polymorphism
        is associated with the prevalence and severity of chronic obstructive pulmonary
        disease in a Japanese population. Respirology. 2012 Jan;17(1):164-71. doi:
        10.1111/j.1440-1843.2011.02069.x.
    30. Tanabe N, Muro S, Hirai T, Oguma T, Terada K, Marumo S, Kinose D, Ogawa E,
        Hoshino Y, Mishima M. Impact of exacerbations on emphysema progression in chronic
        obstructive pulmonary disease. Am J Respir Crit Care Med. 2011 Jun 15;183(12):1653-9. Epub 2011 Mar 11.

        2010年

    31. Nishioka M, Ogawa E, Kinose D, Haruna A, Ohara T, Ito I, Hoshino Y, Ito Y,
        Matsumoto H, Niimi A, Mio T, Chin K, Hirai T, Muro S, Mishima M.
        Lipopolysaccharide induced connective tissue growth factor gene expression in
        human bronchial epithelial cells. Respirology. 2010 May;15(4):669-76. Epub 2010
        Mar 29.
    32. Haruna A, Muro S, Nakano Y, Ohara T, Hoshino Y, Ogawa E, Hirai T, Niimi A,
        Nishimura K, Chin K, Mishima M. CT scan findings of emphysema predict mortality
        in COPD. Chest. 2010 Sep;138(3):635-40. Epub 2010 Apr 9.
    33. Haruna A, Oga T, Muro S, Ohara T, Sato S, Marumo S, Kinose D, Terada K,
        Nishioka M, Ogawa E, Hoshino Y, Hirai T, Chin K, Mishima M. Relationship between
        peripheral airway function and patient-reported outcomes in COPD: a cross-sectional study. BMC Pulm Med. 2010 Mar 7;10:10.

        2009年

    34. IL-9 induces CCL11 expression via STAT3 signalling in human airway smooth muscle cells.Yamasaki A, Saleh A, Koussih L, Muro S, Halayko AJ, Gounni AS. PLoS One. 2010 Feb 12;5(2):e9178.
    35. Sakai H, Nakano Y, Muro S, Hirai T, Takubo Y, Oku Y, Hamakawa H, Takahashi A,
        Sato T, Chen F, Sahara H, Fujinaga T, Sato K, Sonobe M, Shoji T, Miyahara R,
        Okubo K, Bando T, Hirata T, Date H, Mishima M. Age-related changes in the trachea
        in healthy adults. Adv Exp Med Biol. 2010;662:115-20.
    36. Terada K, Muro S, Ohara T, Kudo M, Ogawa E, Hoshino Y, Hirai T, Niimi A, Chin
        K, Mishima M. Abnormal swallowing reflex and COPD exacerbations. Chest. 2010
        Feb;137(2):326-32. Epub 2009 Sep 25.
    37. Terada K, Muro S, Ohara T, Haruna A, Marumo S, Kudo M, Ogawa E, Hoshino Y,
        Hirai T, Niimi A, Mishima M. Cough-reflex sensitivity to inhaled capsaicin in
        COPD associated with increased exacerbation frequency. Respirology. 2009
        Nov;14(8):1151-5. Epub 2009 Sep 16.

        2008年

    38. Ogawa E, Nakano Y, Ohara T, Muro S, Hirai T, Sato S, Sakai H, Tsukino M,
        Kinose D, Nishioka M, Niimi A, Chin K, Paré PD, Mishima M. Body mass index in
        male patients with COPD: correlation with low attenuation areas on CT. Thorax.
        2009 Jan;64(1):20-5. Epub 2008 Oct 13.
    39. Sato, A., et al., Thioredoxin-1 ameliorates cigarette smoke-induced lung inflammation and emphysema in mice. J Pharmacol Exp Ther, 2008. 325(2): p. 380-8.
    40. Ohara, T., et al., Longitudinal study of airway dimensions in chronic obstructive pulmonary disease using computed tomography. Respirology, 2008. 13(3): p. 372-8.
    41. Terada, K., et al., Impact of gastro-oesophageal reflux disease symptoms on chronic obstructive pulmonary disease exacerbation. Thorax, 2008.
    42. Ohara, T., et al., Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest, 2008.
        

        2007年以前

    43. Sato, A., et al., Morphological mechanism of the development of pulmonary emphysema in klotho mice. Proc Natl Acad Sci U S A, 2007. 104(7): p. 2361-5.
    44. Ohara, T., et al., Comparison of airway dimensions in different anatomic locations on chest CT in patients with COPD. Respirology, 2006. 11(5): p. 579-85.
    45. Ito, I., et al., Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med, 2005. 172(11): p. 1378-82.
    46. Ito, I., et al., Risk and severity of COPD is associated with the group-specific component of serum globulin 1F allele. Chest, 2004. 125(1): p. 63-70.
    47. Muro, S., et al., 5-oxo-6,8,11,14-eicosatetraenoic acid induces the infiltration of granulocytes into human skin. J Allergy Clin Immunol, 2003. 112(4): p. 768-74.
    48. Muro, S., et al., Expression of IL-15 in inflammatory pulmonary diseases. J Allergy Clin Immunol, 2001. 108(6): p. 970-5.
    49. Muro, S., E.M. Minshall, and Q.A. Hamid, The pathology of chronic asthma. Clin Chest Med, 2000. 21(2): p. 225-44.
    50. Nakano, Y., et al., Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med, 2000. 162(3 Pt 1): p. 1102-8.
    51. Muro, S., et al., Distorted trachea in patients with chronic obstructive pulmonary disease. Respiration, 2000. 67(6): p. 638-44.
    52. Nakano, Y., et al., Comparison of low attenuation areas on computed tomographic scans between inner and outer segments of the lung in patients with chronic obstructive pulmonary disease: incidence and contribution to lung function. Thorax, 1999. 54(5): p. 384-9.
    53. Mishima, M., et al., Optimized scanning conditions of high resolution CT in the follow-up of pulmonary emphysema. J Comput Assist Tomogr, 1999. 23(3): p. 380-4.
    54. Mishima, M., et al., Respiratory impedance during positive expiratory airway pressure in patients with chronic obstructive pulmonary disease. Front Med Biol Eng, 1999. 9(1): p. 63-73.
    55. Mishima, M., et al., Complexity of terminal airspace geometry assessed by lung computed tomography in normal subjects and patients with chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A, 1999. 96(16): p. 8829-34.
    56. Takubo, Y., et al., Age-associated changes in elastin and collagen content and the proportion of types I and III collagen in the lungs of mice. Exp Gerontol, 1999. 34(3): p. 353-64.
    57. Muro, S., et al., The effect of the level of ventilatory assist on the level of respiratory drive in decerebrate cats. Respir Physiol, 1997. 109(3): p. 205-17.
    58. Mishima, M., et al., Relationship between dyspnea in daily life and psycho-physiologic state in patients with chronic obstructive pulmonary disease during long-term domiciliary oxygen therapy. Intern Med, 1996. 35(6): p. 453-8.

• 喘息・慢性咳嗽

  • 2013年

    1. Nagasaki T, Matsumoto H, Kanemitsu Y, Izuhara K, Tohda Y, Kita H, Horiguchi T, Kuwabara K, Tomii K, Otsuka K, Fujimura M, Ohkura N, Tomita K, Yokoyama A, Ohnishi H, Nakano Y, Oguma T, Hozawa S, Nagasaki T, Ito I, Oguma T, Inoue H, Tajiri T, Iwata T, Izuhara Y, Ono J, Ohta S, Yokoyama T, Niimi A, Mishima M. Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes. J Allergy Clin Immunol, in press
    2. Kanemitsu Y, Matsumoto H, Mishima M, on behalf of the KiHAC Respiratory Medicine Group. Factors contributing to an accelerated decline in pulmonary function. Allergol Int, in press.

    第9回アレルギー学会大会賞受賞論文

    3. Matsumoto H. Serum periostin: a novel biomarker for asthma management. Allergol Int, in press
    4. Tajiri T, Niimi A, Matsumoto H, Ito I, Oguma T, Otsuka K, Takeda T, Nakaji H, Inoue H, Iwata T, Nagasaki T, Mishima M. Prevalence and Clinical Relevance of Allergic Rhinitis in Patients with Classic Asthma and Cough Variant Asthma. Respiration, in press
    5. Oguma T, Hirai T, Niimi A, Matsumoto H, Muro S, Shigematsu M, Nishimura T, Kubo Y, Mishima M. Limitation of airway dimension measurement on images obtained using multi-detector row computed tomography. PLoS One. 2013 Oct 8;8(10):e76381. doi: 10.1371/journal.pone.0076381.
    6. Matsumoto H. Effects of inflammatory cytokines on Ca2+ homeostasis in airway smooth muscle cells. in “Calcium Signaling in Airway Smooth Muscle Cells” Wang YX. ed. Springer, 2013.
    7. Tajiri T, Matsumoto H, Niimi A, Ito I, Oguma T, Nakaji H, Inoue H, Iwata T, Nagasaki T, Kanemitsu Y, Petrova G, Mishima M. Association of eosinophilic inflammation with FKBP51 expression in sputum cells in asthma. PLoS ONE 2013, 8; 365284. doi:10.1371/journal.pone.0065284
    8. Kanemitsu Y, Matsumoto H, Izuhara K, Tohda Y, Kita H, Horiguchi T, Kuwabara K, Tomii K, Otsuka K, Fujimura M, Ohkura N, Tomita K, Yokoyama A, Ohnishi H, Nakano Y, Oguma T, Hozawa S, Nagasaki T, Ito I, Oguma T, Inoue H, Tajiri T, Iwata T, Izuhara Y, Ono J, Ohta S, Tamari M, Hirota T, Yokoyama T, Niimi A, Mishima M. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol, in press
    9. Tajiri T, Matsumoto H, Hiraumi H, Ikeda H, Morita K, Izuhara K, Ono J, Ohta S, Ito I, Oguma T, Nakaji H, Inoue H, Iwata T, Nagasaki T, Kanemitsu Y, Ito J, Niimi A, Mishima M. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol, 2013, 110:387-8. doi: 10.1016/j.anai.2013.01.024.
    10. Nagasaki T, Matsumoto H. Influences of smoking and aging on allergic airway inflammation in asthma. Allergol Int, 2013, 62:171-9, doi: 10.2332/allergolint.12-RA-0523. 第8回アレルギー学会大会賞受賞論文
    11. Nagasaki T, Matsumoto H, Nakaji H, Niimi A, Ito I, Oguma T, Muro S, Inoue H, Iwata T, Tajiri T, Kanemitsu Y, Mishima M. Smoking attenuates the age-related decrease in IgE levels and maintains eosinophilic inflammation. Clin Exp Allergy, 2013, 43:608-15, doi: 10.1111/cea.12073, Editor’s Choiceに選ばれました
    12. Nakaji H, Petrova G, Matsumoto H, Iwata T, Ito I, Oguma T, Inoue H, Tajiri T, Nagasaki T, Kanemitsu Y, Niimi A, Misima M. Effects of 24-week add-on treatment with ciclesonide and montelukast on small airways inflammation in asthma. Ann Allergy Asthma Immunol, 2013 110:198-203.
        

        2012年

    13. Matsumoto H, Hirata Y, Otsuka K, Iwata T, Inazumi A, Niimi A., Ito I, Ogawa E, Muro S, Sakai H, Chin K, Oku Y, Mishima M.Interleukin-13 enhanced Ca2+ oscillations in airway smooth muscle cells. Cytokine, 2012;57:19-24.
    14. Matsumoto H, Tabuena R, Niimi A, Inoue H. Ito I, Yamaguchi M, Otsuka K, Takeda T, Oguma T, Nakaji H, Tajiri T, Iwata T, Nagasaki T, Jinnai M, Matsuoka H, Mishima M. Cough triggers and their pathophysiology in patients with prolonged or chronic cough. Allergol Int, 2012;61:123-32. 第6回アレルギー学会大会賞受賞論文
    15. Otsuka K, Matsumoto H, Niimi A, Muro S, Ito I, Takeda T, Terada K, Yamaguchi M, Matsuoka H, Jinnai M, Oguma T, Nakaji H, Inoue H, Tajiri T, Iwata T, Chin K, Mishima M. Sputum YKL-40 levels and pathophysiology of asthma and chronic obstructive pulmonary disease. Respiration, 2012;83:507-19.
    16. Takemura M, Niimi A, Matsumoto H, Ueda T, Matsuoka H, Yamaguchi M, Jinnai M, Chin K, Mishima M. Clinical, Physiological and Anti-Inflammatory Effect of Montelukast in Patients with Cough Variant Asthma.Respiration, 2012;83:308-15.
    17. Ito Y, Hirai T, Maekawa K, Fujita K, Imai S, Tatsumi S, Handa T, Matsumoto H, Muro S, Niimi A, Mishima M.　Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis, 2012;16:408-14.
        

        2011年

    18. Otsuka K, Niimi A, Matsumoto H, Ito I, Yamaguchi M, Matsuoka H, Jinnai M, Oguma T, Takeda T, Nakaji H, Chin K, Sasaki K, Aoyama N, Mishima M. Plasma substance P levels in patients with persistent cough. Respiration, 2011;82:431-8.
    19. Nakaji H, Matsumoto H, Niimi A, Handa H, Ito I, Kanai M., Tabata H., Sakai H., Kobashi Y., Mochizuki Y., Chin K, Mishima M. Eosinophils and macrophages are involved in nitrosative stress in chronic eosinophilic pneumonia. Nitric Oxide, 2011;24:173-5.
    20. Matsumoto H, Niimi A, Jinnai M, Nakaji H, Takeda T, Oguma T, Otsuka K, Inoue H, Yamaguchi M, Matsuoka H, Ito I, Hirai T, Chin K, Mishima M. Association of alveolar nitric oxide levels with pulmonary function and its reversibility in stable asthma. Respiration, 2011;81:311-7.
    21. Matsumoto H, Niimi A, Takemura M, Ueda T, Yamaguchi M, Matsuoka H, Jinnai M, Takeda T, Otsuka K, Oguma T, Handa T, Hirai T, Chin K, Mishima M. Long-term changes in airway-wall thickness on computed tomography in asthmatic patients. J Invest Allergol Clin Immunol, 2011;21:113-9.
    22. Kiyokawa H, Matsumoto H, Nakaji H, Niimi A, Ito I, Ono K, Takeda T, Oguma T, Otsuka K, Mishima M. Centrilobular opacities in the asthmatic lung successfully treated wtih inhaled ciclesonide and tiotropium: with assessment of alveolar nitric oxide levels. Allergol Int, 2011;60:381-5.
    23. Hirota T, Takahashi A, Kubo M, Tsunoda T, Tomita K, Doi S, Fujita K, Miyatake A, Enomoto T, Miyagawa T, Adachi M, Tanaka M, Niimi A, Matsumoto H, Ito I, Masuko H, Sakamoto T, Hizawa T, Taniguchi M, Lima J, Irvin C, Peters S, Himes B, Litonjua A, Tantisira K, Weiss S, Kamatani N, Nakamura Y, Tamari M. Genome-wide association study identifies three new susceptibility loci for adult asthma in the Japanese population. Nat Genet 2011;43:893-6.
    24. Niimi A. Structural changes in the airways: Cause or effect of chronic cough. Pulm Pharmacol Ther, 2011;24:328-33.
    25. Niimi A. Cough in asthma. Current Respiratory Medicine Reviews, 2011;7:47-54.
        

        2010年

    26. Matsuoka H, Niimi A, Matsumoto H, Takemura M, Ueda T, Yamaguchi M, Jinnai M, Inoue H, Ito I, Chin K, Mishima M. Inflammatory subtypes in cough variant asthma: Association with maintenance doses of inhaled corticosteroids. Chest. 2010;138:1418-25.
    27. Kanatani K, Ito I, Al-Delaimy WK, Adachi Y, Mathews WC, Ramsdell JW, Toyama Asian Desert Dust and Asthma Study Team. Desert-dust exposure is associated with increased risk of asthma hospitalization in children. Am J Respir Crit Care Med 2010;182:1475-81.
    28. Nishioka M, Ogawa E, Kinose D, Haruna A, Ohara T, Ito I, Hoshino Y, Ito Y, Matsumoto H, Niimi A, Mio T, Chin K, Hirai T, Muro S, Mishima M. Lipopolysaccharide induced connective tissue growth factor gene expression in human bronchial epithelial cells. Respirology 2010;15:669076.
    29. Ito I, Kadowaki S, Tanabe N, Haruna A, Kase M, Yasutomo Y, Tsukino M, Nakai A, Matsumoto H, Niimi A, Chin K, Ichiyama S, Mishima M. Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: Comparison with imipenem/cilastatin. Pulm Pharmacol Ther. 2010 Oct;23(5):403-410.
    30. Takeda T, Oga T, Niimi A, Matsumoto H, Ito I, Yamaguchi M, Matsuoka H, Jinnai M, Otsuka K, Oguma T, Nakaji H, Chin K, Mishima M. Relationship between small airway function and health status, dyspnea and disease control in asthma. Respiration 2010;80:120-126.
    31. Jinnai M, Niimi A, Ueda T, Matsuoka H, Takemura M, Yamaguchi M, Otsuka K, Oguma T, Takeda T, Ito I, Matsumoto H, Mishima M. Induced sputum concentrations of mucin in patients with asthma and chronic cough. Chest 2010; 137(5):1122-9.
        

        2009年

    32. Niimi A, Matsumoto H, Mishima M. Eosinophilic airway disorders associated with chronic cough. Pulm Pharmacol Ther. 2009;22:114-20
    33. Matsuoka H, Niimi A, Matsumoto H, Ueda T, Takemura M, Yamaguchi M, Jinnai M, Otsuka K, Oguma T, Takeda T, Ito I, Chin K, Amitani R, Mishima M. Specific IgE response to Trichophyton and asthma severity. Chest 2009;135:898-903.
    34. Matsumoto H, Niimi A, Takemura M, Ueda T, Yamaguchi M, Matsuoka H, Jinnai M, Chin K, Mishima M. Features of cough variant asthma and classic asthma during methacholine-induced brochoconstriction: a cross-sectional study. Cough 2009;5:3.
    35. Yamaguchi M, Niimi A, Ueda T, Takemura M, Matsuoka H, Jinnai M, Otsuka K, Oguma T, Takeda T, Ito I, Matsumoto H, Hirai T, Chin K, Mishima M. Effect of inhaled corticosteroids on small airways in asthma: investigation using impulse oscillometry. Pulm Pharmacol Ther 2009;22:326-32.
    36. Ito I, Fixman ED, Asai K, Yoshida M, Gounni AS, Martin JG, Hamid Q. Platelet-derived growth factor and transforming growth factor-beta modulate the expression of matrix metalloproteinases and migratory function of human airway smooth muscle cells. Clin Exp Allergy. 2009 Sep;39(9):1370-80
    37. Ito I, Ishida T, Togashi K, Niimi A, Koyama H, Ishimori T, Kobayashi H, Mishima M. Differentiation of bacterial and non-bacterial community-acquired pneumonia by thin-section computed tomography. Eur J Radiol. 2009;72:388-95.
        

        2008年

    38. Takemura M, Quarcoo D, Niimi A, Dinh QT, Geppetti P, Fischer A, Chung KF, Groneberg DA. 　Is TRPV-1 a useful target in respiratory diseases? Pulm Pharmacol Ther 2008;21:833-9.
    39. Niimi A. Cough variant asthma: a major cause of chronic cough. Clin Pulm Med 2008;15:189-196.
    40. Ueda T, Niimi A, Matsumoto H, Takemura M, Yamaguchi M, Matsuoka H, Jinnai M, Chin K, Minakuchi M, Cheng L, Shirakawa T, Mishima M. TGFB1 promoter polymorphism C-509T and pathophysiology of asthma. J Allergy Clin Immunol 2008;121:659-664.
    41. Matsuoka H, Niimi A, Matsumoto H, Ueda T, Takemura M, Yamaguchi M, Jinnai M, Chang L, Otsuka K, Oguma T, Takeda T, Chin K, Mishima M. Patients’ characteristics associated with unsuccessful sputum induction in asthma. J Allergy Clin Immunol 2008;121:774-6.
    42. Yamaguchi M, Niimi A, Matsumoto H, Ueda T, Takemura M, Matsuoka H, Jinnai M, Otsuka K, Oguma T, Takeda T, Ito I, Chin K, Mishima M. Sputum levels of transforming growth factor-b・ in asthma: Relation to clinicoradiological findings. J Invest Allergol Clin Immunol 2008;18:202-6.
    43. Jinnai M, Niimi A, Takemura M, Matsumoto H, Konda Y, Mishima M. Gastroesophageal reflux-associated chronic cough in an adolescent and the diagnostic implications: a case report. Cough. 2008 Jul 15;4:5.
    44. Matsumoto H. Sputum inflammatory markers in cough variant asthma: therapeutic implications.　Multidisciplinary Respiratory Medicine 2008; 3:2217-222.
        

        2007年

    45. Takemura M, Niimi A, Matsumoto H, Ueda T, Yamaguchi M, Matsuoka H, Jinnai M, Chin K, Mishima M. Atopic features of cough variant asthma and classic asthma with wheezing. Clin Exp Allergy 2007;37:1833-9
    46. Yamaguchi M, Niimi A, Minakuchi M, Matsumoto H, Shimizu K, Chin K, Mishima M. Corticosteroid-induced myopathy mimicking therapy-resistant asthma. Ann Allergy Asthma Immunol 2007;99:371-4.
    47. Matsumoto H, Niimi A, Takemura M, Ueda T, Yamaguchi M, Matsuoka H, Jinnai M, Chin K, Mishima M. Prevalence and clinical manifestations of gastro-oesophageal reflux-associated chronic cough in the Japanese population. Cough 2007 Jan 8;3:1.
    48. Matsumoto H, Niimi A, Tabuena RP; Takemura M, Ueda T, Yamaguchi M, Matsuoka H, Jinnai M, Chin K, Mishima M. Airway wall thickening in patients with cough variant asthma and nonasthmatic chronic cough. Chest 2007;131:1042-9..
    49. Niimi A. Geography and cough aetiology. Pulm Pharmacol Ther 2007;20:383-387.
    50. Leung SY, Niimi A, Williams AS, Nath P, Blanc FX, Din QT, Chung KF. Inhibition of citric acid- and capsaicin-induced cough by novel TRPV-1 antagonist, V112220, in guinea-pig. Cough. 2007 Dec 23;3:10
    51. Matsumoto H, Moir LM, Oliver BG, Burgess JK, Roth M, Black JL, McParland BE. Comparison of gel contraction mediated by airway smooth muscle cells from patients with and without asthma. Thorax. 2007;62:848-54.
    52. Borger P, Matsumoto H, Boustany S, Gencay MM, Burgess JK, King GG, Black JL, Tamm M, Roth M. Disease-specific expression and regulation of CCAAT/enhancer-binding proteins in asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2007;119:98-105.
    53. Ito I, Laporte JD, Fiset PO, Asai K, Yamauchi Y, Martin JG, Hamid Q. Down-regulation of a Disintegrin and Metalloproteinase-33 by Interferon-gamma in Human Airway Smooth Muscle Cells. J Allergy Clin Immunol 2007;119:89-97.
        

        2006年

    54. Matsumoto H, Niimi A, Takemura M, Ueda T, Tabuena R, Yamaguchi M, Matsuoka H, Hirai T, Muro S, Ito Y, Mio T, Chin K, Nishiyama H, Mishima M. Prognosis of cough variant asthma: a retrospective analysis. J Asthma 2006;43:131-5.
    55. Takemura M, Matsumoto H, Niimi A, Ueda T, Matsuoka H, Yamaguchi M, Jinnai M, Muro S, Hirai T, Ito Y, Nakamura T, Mio T, Chin K, Mishima M. High sensitivity C-reactive protein in asthma. Eur Respir J 2006;27:908-12.
    56. Leung SY, Niimi A, Noble A, Oates T, Williams A, Medicherla S, Protter AA, Chung KF. Effect of TGF-β receptor I kinase inhibitor, SD-208, in chronic allergic airway inflammation and remodeling. J Pharmacol Exp Ther. 2006;319:586-94
    57. Ueda T, Niimi A, Matsumoto H, Takemura M, Hirai T, Yamaguchi M, Matsuoka H, Jinnai M, Muro S, Chin K, Mishima M. Role of small airways in asthma: Investigation using high-resolution computed tomography. J Allergy Clin Immunol 2006;118:1019-25.
    58. Committee for the Japanese Respiratory Society Guidelines for Management of Cough; Kohno S, Ishida T, Uchida Y, Kishimoto H, Sasaki H, Shioya T, Tokuyama K, Niimi A, Nishi K, Fujimura M, Matsuse H, Suzaki H. The Japanese Respiratory Society guidelines for management of cough. Respirology 2006;11 Suppl 4:S135-86.
        

        2005年

    59. Niimi A, Kihara Y, Sumita Y, Okano Y, Tambara K, Fujita M. Cough reflex by ventricular premature contractions. Int Heart J 2005;46:923-6.
    60. Matsumoto H, Niimi A, Takemura M, Ueda T, Minakuchi M, Tabuena RP, Chin K, Mio T, Ito Y, Muro S, Hirai T, Morita S, Fukuhara S, Mishima M. Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. Thorax 2005;60:277-281.
    61. Niimi A, Torrego A, Nicholson AG, Cosio BG, Oates TB, Chung KF. Nature of airway inflammation and remodeling in chronic cough. J Allergy Clin Immunol. 2005;116:565-70
    62. Ito I, Nagai S, Kitaichi M, Nicholson AG, Johkoh T, Noma S, Kim DS, Handa T, Izumi T, Mishima M. Pulmonary Manifestations of Primary Sjogren’s Syndrome: A Clinical, Radiologic, and Pathologic Study. Am J Respir Crit Care Med 2005;172:632-8
    63. Ito I, Nagai S, Handa T, Muro S, Hirai T, Tsukino M, Mishima M. Matrix Metalloproteinase-9 Promoter Polymorphism Associated with Upper Lung Dominant Emphysema. Am J Respir Crit Care Med 2005;172:1378-82.
        

        2004年

    64. Takemura M, Niimi A, Minakuchi M, Matsumoto H, Ueda T, Chin K, Mishima M. Bronchial dilatation in asthma: relation to clinical and sputum indices. Chest 2004;125:1352-1358.
    65. Niimi A, Matsumoto H, Amitani R, Nakano Y, Sakai H, Takemura M, Ueda T, Chin K, Itoh H, Ingenito EP, Mishima M. Effect of short-term treatment with inhaled corticosteroid on airway wall thickening in asthma. Am J Med 2004;116:725-731.
    66. Niimi A, Matsumoto H, Takemura M, Ueda T, Nakano Y, Mishima M. Clinical assessment of airway remodeling in asthma: utility of computed tomography. Clin Rev Allergy Immunol 2004;27:45-57.
    67. Niimi A, Nguyen LT, Usmani O, Mann BS, Chung KF. Reduced pH and chloride levels in exhaled breath condensate of patients with chronic cough. Thorax 2004;59:608-612.
    68. Niimi A, Chung KF. Airway inflammation and remodelling changes in patients with chronic cough: do they tell us about the cause of cough? Pulm Pharmacol Ther 2004;17:441-446.
    69. Groneberg DA, Niimi A, Dinh QT, Cosio B, Hew M, Fischer A, Chung KF. Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough. Am J Respir Crit Care Med 2004;170:1276-80
    70. Ueda T, Tabuena R, Matsumoto H, Takemura M, Niimi A, Chin K, Mishima M Successful weaning using noninvasive positive pressure ventilation in a patient with status asthmaticus. Intern Med 2004;43:1060-2.
    71. Ito I, Nagai S, Hoshino Y, Muro S, Hirai T, Tsukino M, Mishima M. Risk and Severity of Chronic Obstructive Pulmonary Disease Is Associated with Gc-globulin 1F Allele. Chest 125: 2004; 63-70.
        

        2003年以前

    72. Niimi A, Matsumoto H, Ueda T, Takemura M, Suzuki K, Tanaka E, Chin K, Mishima M, Amitani R. Impaired cough reflex in patients with recurrent pneumonia. Thorax 2003;58:152-153.
    73. Niimi A, Matsumoto H, Takemura M, Ueda T, Chin K, Mishima M. Relationship of airway wall thickness to airway sensitivity and airway reactivity in asthma. Am J Respir Crit Care Med 2003;168:983-8.
    74. Minakuchi M, Niimi A, Matsumoto H, Amitani R, Mishima M. Chronic eosinophilic pneumonia: treatment with inhaled corticosteroid. Respiration 2003;70:362-366, 2003.
    75. Gibson PG, Fujimura M, Niimi A. Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax 2002;57:178-182.
    76. Nakano Y, Muller NL, King GG, Niimi A, Kalloger SE, Mishima M, Pare PD. Quantitative assessment of airway remodeling using high-resolution CT. Chest 2002;122:271s-275s.
    77. Ito I, Ishida T, Mishima M, Osawa M, Arita M, Hashimoto T, Kishimoto T. Familial Cases of Psittacosis: Possible Person-to-person Transmission. Intern Med 41: 2002; 580-3.
    78. Ito I, Ishida T, Hashimoto T, Arita M, Osawa M, Mishima M, Nonoyama S. Hyper-IgM Syndrome with Disseminated Tuberculosis. Scand J Infect Dis 34: 2002; 305-7.
    79. Ito I, Naito J, Kadowaki S, Mishima M, Ishida T, Hongo T, Ma L, Ishii Y, Matsumoto T, Yamaguchi K. Hot spring bath and Legionella pneumonia: an association confirmed by genomic identification. Intern Med 41: 2002; 859-63.
    80. Ito I, Ishida T, Osawa M, Arita M, Hashimoto T, Hongo T, Mishima M. Culturally verified Mycoplasma pneumoniae pneumonia in Japan: a long-term observation from 1979-99. Epidemiol Infect 127: 2001; 365-7.
    81. Ito I, Ishida T, Hashimoto T, Arita M, Osawa M, Yokota T, Ishimori T. Hypopituitarism due to pituitary metastasis of lung cancer: case of a 21-year-old man. Intern Med. 40: 2001; 414-7.
    82. Matsumoto H, Niimi A, Minakuchi M, Izumi T. Serum eosinophil cationic protein measured during exacerbation of asthma. Characteristics of patients with low titres. Clin Exp Allergy 2001;31:637-643
    83. Matsumoto H, Ishihara K, Hasegawa T, Umeda B, Niimi A, Hino M. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatics: a 4-year longitudinal study. Chest 2001;120:1468-1473.
    84. Niimi A, Matsumoto H, Amitani R, Nakano Y, Mishima M, Minakuchi M, Nishimura K, Itoh H, Izumu T. Airway wall thickness in asthma assessed by computed tomography. Relation to clinical indices. Am J Respir Crit Care Med 2000;162:1518-1523
    85. Niimi A, Matsumoto H, Minakuchi M, Kitaichi M, Amitani R. Airway remodelling in cough-variant asthma. Lancet 2000;356:564-565.
    86. Matsumoto H, Niimi A, Suzuki K, Kawai M, Matsui Y, Amitani R: Allergic granulomatous angiitis (Churg-Strauss syndrome) associated with allergic bronchopulmonary candidiasis. Respiration 2000;67:577-579.
    87. Matsumoto H, Suzuki K, Watanabe I, Kimoto T, Tsuyuguchi K, Niimi A, Tanaka E, Murayama T, Amitani R. Recurrent hemoptysis in tuberculosis with non-cavitary lung disease as a symptom of mild hemophilia A in a young adult. Intern Med 2000;39:63-65.
    88. Ito I, Ishida T, Hashimoto T, Arita M, Osawa M, Tsukayama C. Familial Cases of Severe Measles Pneumonia. Intern Med 39: 2000; 670-4.
    89. Niimi A, Matsumoto H. Serum measurement of eosinophil cationic protein in the management of asthma. Curr Opin Pulm Med 1999;5:111-117.
    90. Tanaka E, Kimoto T, Tsuyuguchi K, Watanaba I, Matsumoto H, Niimi A, Suzuki K, Murayama T, Amitani R, Kuze F. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999;160:866-872.
    91. Niimi A, Amitani R, Suzuki K, Tanaka E, Murayama T, Kuze F: Eosinophil cationic protein as a marker of eosinophilic inflammation in asthma.　Clin Exp Allergy 1998;28:233-240.
    92. Matsumoto H, Tsuyuguchi K, Suzuki K, Tanaka E, Amitani R, Kuze F. Evaluation of Roche Amplicor PCR assay for Mycobacterium avium complex in bronchial washing. Int J Tuberc Lung Dis 1998; 2: 935-940.
    93. Niimi A, Amitani R, Suzuki K, Tanaka E, Murayama T, Kuze F. Eosinophilic inflammation in cough variant asthma.　Eur Respir J 1998;11:1064-1069.
    94. Tsuyuguchi K, Amitani R, Matsumoto H, Tanaka E, Suzuki K, Yanagihara K, Mizuno H, Hitomi S, Kuze F. A resected case of Mycobacterium szulgai pulmonary disease. Int J Tuberc Lung Dis 1998;2:258-260.
    95. Niimi A, Amitani R, Watanabe I, Kuze F: Non-asthmatic seasonal cough in an atopic subject: successful treatment with specific immunotherapy. 　J Jpn Soc Bronchol 1997;19: 527-530.
    96. Matsumoto H, Suzuki K, Tsuyuguchi K, Tanaka E, Amitani R, Maeda A, Yamamoto K, Sasada M, Kuze F. Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG: cytokine regulation and effect of NK cells. Infect Immun 1997;65: 4405-4410.
    97. Tanaka E, Amitani R, Niimi A, Suzuki K, Murayama T, Kuze F. Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease.　Am J Respir Crit Care Med 1997;155: 2041-2046.
    98. Suzuki K, Tsuyuguchi K, Matsumoto H, Yamamoto T, Hashimoto T, Tanaka E, Amitani R, Kuze F. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages. Int J Tuberc Lung Dis 1997;1:460-467.
    99. Niimi A, Amitani R, Yamada K, Tanaka K, Kuze F. Late respiratory response and associated eosinophilic inflammation induced by repeated exposure to toluene diisocuanate in guinea pigs. J Allergy Clin Immunol 1996;97:1308-1319.
    100. Amitani R, Nishimura K, Niimi A, Kobayashi H, Nawada R, Murayama T, Taguchi H, Kuze F: Mucoid impaction of the bronchi caused by monokaryotic mycelium of Schizophyllum commune. Clin Infect Dis 1996;22:146-148.
    101. Yamada K, Amitani R, Niimi A, Kuze F. Interstitial pneumonitis-like lesions in guinea pigs following repeated exposure to toluene diisocyanate. Eur Respir J 1995;8:1300-1306.
    102. Amitani R, Murayama T, Nawada R, Lee W-J, Niimi A, Suzuki K, Tanaka E, Kuze F. Aspergillus culture filtrates and sputum sols from patients with pulmonary aspergillosis cause damage to human respiratory ciliated epithelium in vitro. Eur Respir J 1995;8: 1681-1687.
    103. Niimi A, Amitani R, Ikeda T, Kubo Y, Tanaka E, Kuze F: Inflammatory bronchial polyps associated with asthma: resolution with inhaled corticosteroid. Eur Respir J 1995;8:1237-1239.

• 感染症

  • 2013年

    1. Maekawa K, Ito Y, Oga T, Hirai T, Kubo T, Fujita K, Imai S, Niimi A, Chin K, Ichiyama S, Togashi K, Mishima M. High-resolution computed tomography and health-related quality of life in Mycobacterium avium complex disease. Int J Tuberc Lung Dis. 2013;17:829-35.
    2. Fujita K, Ito Y, Hirai T, Maekawa K, Imai S, Tatsumi S, Niimi A, Iinuma Y, Ichiyama S, Mishima M. Genetic relatedness of Mycobacterium avium-intracellulare complex isolates from patients with pulmonary MAC disease and their residential soils. Clin Microbiol Infect. 2013;19:537-41.
       

       2012年

    3. Ito Y, Hirai T, Maekawa K, Fujita K, Imai S, Tatsumi S, Handa T, Matsumoto H, Muro S, Niimi A, Mishima M. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis. 2012;16:408-14.
    4. Imai S, Ito Y, Hirai T, Imai H, Ito I, Maekawa K, Chin K, Ichiyama S, Uemoto S, Mishima M. Clinical features and risk factors of tuberculosis in living-donor liver transplant recipients. Transpl Infect Dis. 2012;14:9-16.
    5. Matsumura Y, Ito Y, Iinuma Y, Yasuma K, Yamamoto M, Matsushima A, Nagao M, Takakura S, Ichiyama S. Quantitative real-time PCR and the (1→3)-β-D-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization. Clin Microbiol Infect. 2012;18:591-7.
       

       2011年

    6. Hamada S, Ito Y, Imai S, Oguma T, Niimi A, Mishima M. Effect of inhaled corticosteroid therapy on CT scan-estimated airway dimensions in a patient with chronic bronchitis related to ulcerative colitis. Chest. 2011;139:930-2.
    7. Maekawa K, Ito Y, Hirai T, Kubo T, Imai S, Tatsumi S, Fujita K, Takakura S, Niimi A, Iinuma Y, Ichiyama S, Togashi K, Mishima M. Environmental risk factors for pulmonary Mycobacterium avium-intracellulare complex disease. Chest. 2011;140:723-9.
    8. Imai S, Ito Y, Ishida T, Hirai T, Ito I, Yoshimura K, Maekawa K, Takakura S, Niimi A, Iinuma Y, Ichiyama S, Mishima M; Kansai Community Acquired Pneumococcal Pneumonia Study Group. Distribution and clonal relationship of cell surface virulence genes among Streptococcus pneumoniae isolates in Japan. Clin Microbiol Infect. 2011;17:1409-14.
    9. Takeda N, Nojima T, Terao C, Yukawa N, Kawabata D, Ohmura K, Usui T, Fujii T, Ito Y, Iinuma Y, Mimori T. Interferon-gamma release assay for diagnosing Mycobacterium tuberculosis infections in patients with systemic lupus erythematosus. Lupus. 2011;20:792-800.
       

       2010年

    10. Osawa M, Ito Y, Ishida T, Imai S, Ichiyama S, Mishima M; Kansai Community Acquired Pneumococcal Pneumonia Study Group.Molecular characterization of quinolone resistance-determining regions and their correlation with serotypes and genotypes among Streptococcus pneumoniae isolates in Japan. Eur J Clin Microbiol Infect Dis. 2010;29:245-8.
        

        2009年

    11. Imai S, Ito Y, Ishida T, Hirai T, Ito I, Maekawa K, Takakura S, Iinuma Y, Ichiyama S, Mishima M; Kansai Community Acquired Pneumococcal Pneumonia Study Group. High prevalence of multidrug-resistant Pneumococcal molecular epidemiology network clones among Streptococcus pneumoniae isolates from adult patients with community-acquired pneumonia in Japan. Clin Microbiol Infect. 2009;15:1039-45
        

        2008年

    12. Isozumi R, Ito Y, Ishida T, Hirai T, Ito I, Maniwa K, Hayashi M, Kagioka H, Hirabayashi M, Onaru K, Tomioka H, Tomii K, Gohma I, Osawa M, Imai S, Takakura S, Iinuma Y, Chin K, Ichiyama S, Mishima M; Kansai Community Acquired Pneumococcal Pneumonia Study Group. Molecular characteristics of serotype 3 Streptococcus pneumoniae isolates among community-acquired pneumonia patients in Japan. J Infect Chemother. 2008;14:258-61
    13. Ishida T, Maniwa K, Kagioka H, Hirabayashi M, Onaru K, Tomioka H, Hayashi M, Tomii K, Gohma I, Ito Y, Hirai T, Ito I, Mishima M. Antimicrobial susceptibilities of Streptococcus pneumoniae isolated from adult patients with community-acquired pneumonia in Japan. Respirology. 2008;13:240-246.
        

        2007年

    14. Ito Y, Osawa M, Isozumi R, Imai S, Ito I, Hirai T, Ishida T, Ichiyama S, Mishima M; Kansai Community Acquired Pneumococcal Pneumonia Study Group. Pneumococcal surface protein A family types of Streptococcus pneumoniae from community-acquired pneumonia patients in Japan. Eur J Clin Microbiol Infect Dis. 2007;26:739-42.
    15. Osawa M, Ito Y, Hirai T, Isozumi R, Takakura S, Fujimoto Y, Iinuma Y, Ichiyama S, Tanaka K, Mishima M. Risk factors for invasive aspergillosis in living donor liver transplant recipients. Liver Transpl. 2007; 13:566-70.
    16. Isozumi R, Ito Y, Ishida T, Osawa M, Hirai T, Ito I, Maniwa K, Hayashi M, Kagioka H, Hirabayashi M, Onari K, Tomioka H, Tomii K, Gohma I, Imai S, Takakura S, Iinuma Y, Ichiyama S, Mishima M; Kansai Community Acquired Pneumococcal Pneumonia Study Group. Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan. J Clin Microbiol. 2007; 45:1440-6.

• 肺がん

  • 2017年度

    1. Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Funazo T, Yasuda Y, Hirai T. EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method. Anticancer Res. 2017 May;37(5):2721-2725.
    2. Yoshida H, Kim YH. Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity. J Thorac Oncol. 2017 May;12(5):e61-e63.
    3. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017 May 10. pii: S0140-6736(17)30565-2.
    4. Takahiro Tsuji, Yuichi Sakamori, Hiroaki Ozasa, Yoshitaka Yagi, Hitomi Ajimizu, Yuto Yasuda, Tomoko Funazo, Takashi Nomizo, Hironori Yoshida, Hiroki Nagai, Ken Maeno, Tetsuya Oguri, Toyohiro Hirai1 and Young Hak Kim. Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer. Oncotarget May 16, 2017 doi: 10.18632/oncotarget.17895
    5. Yuto Yasuda, Takashi Nomizo, Hiroaki Ozasa, Tomoko Funazo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Tomohiro Handa, Takeshi Kubo, Young Hak Kim A retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease Mol Clin Oncol. 2017 In press
    6. Tomoko Funazo, Takashi Nomizo, Young Hak Kim, Liver metastasis is associated with poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. J Thorac Oncol; 2017 in press.
    7. Nobukazu Agatsuma, Yuto Yasuda, Hiroaki Ozasa. Malignant pleural mesothelioma harboring both G719C and S768I mutations of EGFR successfully treated with afatinib. J Thorac Oncol; 2017 in press.
    8. Yuto Yasuda, Yasuyo Nishikawa, Yuichi Sakamori, Makoto Terao, Kentaro Hashimoto, Tomoko Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Hiroki Nagai, Hiroaki Ozasa, Toyohiro Hirai, Young Hak Kim. Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase rearranged non-small cell lung cancer patient. Mol Clin Oncol; 2017 in press.

    2016年度

    1. Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Nakaoku T, Yagi Y, Tsuji T, Nomizo T, Mishima M.Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer. Mol Clin Oncol. 2016 Jul;5(1):213-215.
    2. Shima H, Ozasa H, Tsuji T, Ajimizu H, Nomizo T, Yagi Y, Sakamori Y, Nagai H, Minamiguchi S, Kim YH, Mishima M. Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report. Mol Clin Oncol. 2016 May;4(5):715-718.
    3. Kim YH. Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancer. J Thorac Dis. 2016 Sep;8(9):2369-2371.
    4. Kim YH. Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol. 2016 Dec;11(12):e151-e152.
    5. Fujita K, Kim YH, Yoshizawa A, Mio T, Mishima M. Concomitant T790M mutation and small-cell lung cancer transformation after acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor. Respirology Case Reports. 2016 Dec 1;5(1): e00206
    6. Kobayashi Y, Azuma K, Nagai H, Kim YH, Togashi Y, Sesumi Y, Chiba M, Shimoji M, Sato K, Tomizawa K, Takemoto T, Nishio K, Mitsudomi T.Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. Mol Cancer Ther. 2017 Feb;16(2):357-364.
    7. Nagai H, Kim YH. Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis. 2017 Mar;9(3):448-451.
    8. Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Yuto Yasuda, Hironori Yoshida, Yoshitaka Yagi, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients Scientific Reports 2017 Mar 23;7:45124

    2015年度

    1. Tsuji T, Kim YH, Ozasa H: Successful treatment with carboplatin and nanoparticle albumin-bound paclitaxel in a patient with pulmonary spindle cell carcinoma. Respiratory Medicine Case Reports 15. 48-50. 2015.
    2. Shima H, Ozasa H, Tsuji T: Response to chemotherapy with carboplatin plus albumin‑bound paclitaxel in a patient with lymphoepithelioma‑like thymic carcinoma: A case report. Molecular and Clinical Oncology. 2015 (in press)
    3. Kunii E, Ozasa H, Oguri T: Reversal of c-MET-mediated Resistance to Cytotoxic Anticancer Drugs by a Novel c-MET Inhibitor TAS-115. Anticancer Res 35(10). 5241-5247. 2015.
    4. Kunii E, Oguri T, Kasai D, Ozasa H: Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer. Cancer Chemother Pharmacol 75(5). 985-991. 2015.
    5. Kohno T, Nakaoku T, Tsuta K: Beyond ALK – RET, ROS1 and other oncogene fusions in lung cancer. Translational Lung Cancer Research 4(2). 156-164. 2015.
    6. Sakamori Y, Kim YH, Yoshida H: Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. Mol Clin Oncol 3(2). 334-340. 2015.
    7. Tokuda S, Kim YH, Matsumoto H: Effects of Hydrostatic Pressure on Carcinogenic Properties of Epithelia. PLoS One 10(12). 2015.
    8. Ajimizu H, Kim YH, Mishima M: Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. Med Oncol 32(2). 477. 2015.
    9. Kim YH, Mishima M: Relevance of platinum sensitivity in patients with relapsed or refractory small-cell lung cancer. J Thorac Oncol 10(5). e35. 2015.
    10. Kim YH, Mishima M: Maintenance Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor after First-Line Chemotherapy in Mutation-Positive Non-Small-Cell Lung Cancer. J Thorac Oncol 10(8). e81-82. 2015.
    11. Kim YH, Mishima M: Bevacizumab in Combination with Chemotherapy or Molecularly Targeted Agents for Non-Small-Cell Lung Cancer with Brain Metastases. J Thorac Oncol 10(8). e76. 2015.
    12. Fujita K, Kim YH, Nakatani K: Rapidly progressive sarcomatoid malignant mesothelioma of the pleura mimicking pulmonary empyema. Clinical Case Reports 3(10). 875-878. 2015.
    13. Shinke H, Masuda S, Togashi Y: Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother Pharmacol 76(5). 989-996. 2015.
    14. Kim YH, Mishima M. Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Mar 1;34(7):767.
    15. Nobashi T, Koyasu S, Nakamoto Y, Kubo T, Ishimori T, Kim YH, Yoshizawa A, Togashi K. Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer. Br J Radiol. 2016 Mar;89(1059):20150618. doi: 10.1259/bjr.20150618. Epub 2016 Jan 12.
    16. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, Katakami N, Yokoyama T, Yoshimori K, Takiguchi Y, Hataji O, Takeda Y, Aoe K, Kim YH, Yokota S, Tabeta H, Tomii K, Ohashi Y, Eguchi K, Watanabe K. Support Care Cancer. 2016 Mar 22.

    2014年度

    1. Ozasa H, Oguri T, Maeno K, Takakuwa O, Kunii E, Yagi Y, Uemura T, Kasai D, Miyazaki M, Niimi A. Significance of c-MET Overexpression in Cytotoxic Anticancer Drug Resistant Small Cell Lung Cancer Cells. Cancer Sci. 2014 May 14
    2. Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, Furuta K, Shimada Y, Ogiwara H, Watanabe S, Nokihara H, Yasuda K, Hiramoto M, Nammo T, Ishigame T, Schetter AJ, Okayama H, Harris CC, Kim YH, Mishima M, Yokota J, Yoshida T, Kohno T. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res. 2014 Jun 15;20(12):3087-93.
    3. Kim YH, Nishimura T, Ozasa H, Nagai H, Sakamori Y, Iwata T, Sunadome H, Nishimura T, Mishima M. Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation. Chemotherapy. 2014 Jul 16;59(6):414-419.
    4. Tsuji T, Tanaka E, Yasuda I, Nakatsuka Y, Kaji Y, Yasuda T, Hashimoto S, Hwang M, Hajiro T, Taguchi Y. Nontuberculous mycobacteria in diffuse panbronchiolitis Respirology. 2015 Jan;20(1):80-6.
    5. Ajimizu H, Kim YH, Mishima M. Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. Med Oncol. 2015 Feb;32(2):477.
    6. Sakamori Y, Kim YH, Yoshida H, Nakaoku T, Nagai H, Yagi Y, Ozasa H, Mishima M. Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. Mol Clin Oncol. 2015 Mar;3(2):334-340.
       

       2013年度

    7. Kasai D, Ozasa H, Oguri T, Miyazaki M, Uemura T, Takakuwa O, Kunii E, Ohkubo H, Maeno K, Niimi A.Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.Anticancer Res. 2013 May;33(5):1935-40.
    8. Kim YH, Hirabayashi M, Kosaka S, Nikaidoh J, Yamamoto Y, Shimada M, Toyazaki T, Nagai H, Sakamori Y, Mishima M.　Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.　Cancer Chemother Pharmacol. 2013 Jun;71(6):1445-51.
    9. Kim YH, Mishima M, Date H.　Combined” small cell and “pure” small cell lung cancer: is there a clinical difference?　Med Oncol. 2013 Jun;30(2):600.
    10. Fukudo M, Ikemi Y, Togashi Y, Masago K, Kim YH, Mio T, Terada T, Teramukai S, Mishima M, Inui KI, Katsura T.　Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer. Clin Pharmacokinet. 2013 Jul;52(7):593-609.
    11. Kuriyama Y, Kim YH, Nagai H, Ozasa H, Sakamori Y, Mishima M.　Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive　lung cancer.　Case Rep Oncol. 2013 Aug 14;6(2):430-3.
    12. Takakuwa O, Maeno K, Kunii E, Ozasa H, Hijikata H, Uemura T, Kasai D, Ohkubo H, Miyazaki M, Oguri T, Niimi A.Involvement of intermediate filament nestin in cell growth of small-cell lung cancer. Lung Cancer. 2013 Aug;81(2):174-9.
    13. Kim YH, Ozasa H, Nagai H, Sakamori Y, Yoshida H, Yagi Y, Nakaoku T, Mishima M. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol. 2013 Sep;8(9):e85-6.
    14. Kim YH, Nagai H, Ozasa H, Sakamori Y, Mishima M. Therapeutic strategy for patients with non-small-cell lung cancer and brain metastases. Biomedical Reports. 2013 Sep;1(5):691-696.
    15. Nagai H, Kitano T, Nishimura T, Yasuda H, Nakata K, Takashima S, Kanai M, Matsumoto S, Mori Y, Kakudo Y, Sato H, Yamaguchi T, Kameno K, Kim YH, Mishima M, Yanagihara K. Use of glucose solution for the alleviation of gemcitabine-induced vascular pain: a double-blind randomized crossover study.　Support Care Cancer. 2013 Dec;21(12):3271-8.
    16. Yagi Y, Kim YH, Tajima N, Baba K, Aihara K, Soo HH, Yamaoka S, Mishima M. Long survival of a small-cell lung cancer patient who received maintenance chemotherapy with irinotecan. Case Rep Oncol. 2013 Nov 14;6(3):569-73.
        

        2012年度

    17. Masago K, Togashi Y, Fujita S, Nagai H, Sakamori Y, Okuda C, Kim YH, Mishima M.　Effect of the BCL2 Gene Polymorphism on Survival in Advanced-Stage Non-Small Cell Lung Cancer Patients Who Received Chemotherapy.　Oncology. 2013 Jan 24;84(4):214-218.
    18. Togashi Y, Masago K, Ito Y, Sakamori Y, Okuda C, Fukuhara A, Nagai H, Kim YH, Mishima M. Pneumocystis jiroveci pneumonia and colonization in patients with advanced lung cancer. Oncol Lett. 2013 Feb;5(2):601-604.
    19. Kim YH, Okuda C, Sakamori Y, Masago K, Togashi Y, Mishima M. Continuous morphine infusion for end-stage lung cancer patients. Oncol Lett. 2013 Mar;5(3):972-974.
    20. Togashi Y, Masago K, Handa T, Tanizawa K, Okuda C, Sakamori Y, Nagai H, Kim YH, Mishima M.　Prognostic Significance of Preexisting Interstitial Lung Disease in Japanese Patients with Small-Cell Lung Cancer.　Clin Lung Cancer. 2012 Jul;13(4):304-11.
    21. Kim YH, Sumiyoshi S, Hashimoto S, Masago K, Togashi Y, Sakamori Y, Okuda C, Mio T, Mishima M.　Expressions of Insulin-Like Growth Factor Receptor-1 and Insulin-Like Growth Factor Binding Protein 3 in Advanced Non-Small-Cell Lung Cancer.　Clin Lung Cancer. 2012 Sep;13(5):385-90.
    22. Sakamori Y, Masago K, Ohmori K, Togashi Y, Nagai H, Okuda C, Kim YH, Ichiyama S, Mishima M.　Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small cell lung cancer.　 Cancer Sci. 2012 Jun;103(6):1065-70.
    23. Togashi Y, Masago K, Kubo T, Fujimoto D, Sakamori Y, Nagai H, Kim YH, Togashi K, Mishima M.　Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma.　Med Oncol. 2012 Dec;29(5):3169-75.
    24. Nagai H, Yasuda H, Hatachi Y, Xue D, Sasaki T, Yamaya M, Sakamori Y, Togashi Y, Masago K, Ito I, Kim YH, Mio T, Mishima M.　Nitric oxide (NO) enhances pemetrexed cytotoxicity via NOcGMP signaling in lung adenocarcinoma cells in vitro and in vivo.　Int J Oncol. 2012 Jul;41(1):24-30.
    25. Togashi Y, Masago K, Hamatani Y, Sakamori Y, Nagai H, Kim YH, Mishima M.　Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature.　Lung Cancer. 2012 Aug;77(2):464-8.
    26. Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T, Mishima M.　Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.　Cancer Chemother Pharmacol. 2012 Sep;70(3):399-405.
    27. Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T,
        Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. Cancer Chemother Pharmacol. 2012 Aug;70(2):271-6.

        2011年度

    28. Kim YH, Mishima M. Second-line chemotherapy for small-Cell Lung Cancer (SCLC). Cancer Treat Rev. 37: 143-50, 2011
    29. Kim YH, Mio T, Masago K, Togashi Y, Sakamori Y, Okuda C, Mishima M. EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy. Oncology Letters. 2: 383-7, 2011
    30. Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Mio T, Mishima M. Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy. Clin Lung Cancer. 12(1):56-61, 2011
    31. Okuda C, Kim YH, Takeuchi K, Togashi Y, Masago K, Sakamori Y, Mio T, Mishima M.Successful treatment with pemetrexed in a patient with mucinous　bronchioloalveolar carcinoma: long-term response duration with mild toxicity. J Thorac Oncol. 6(3):641-2, 2011
    32. Kim YH, Ishii G, Ochiai A.　Excision repair cross-complementing-1 for small cell lung cancer. J Thorac Oncol. 6(3):652, 2011
    33. Masago K, Fujita S, Kim YH, Hatachi Y, Fukuhara A, Irisa K, Nagai H, Sakamori Y, Togashi Y, Mio T, Mishima M. Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer. Cancer Chemother Pharmacol. 67(2):325-30, 2011
    34. Masago K, Fujita S, Mio T, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Irisa K, Sakamori Y, Mishima M. Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer. Med Oncol. 28(1):351-6, 2011
    35. Togashi Y, Masago K, Kubo T, Sakamori Y, Kim YH, Hatachi Y, Fukuhara A, Mio T, Togashi K, Mishima M. Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. Cancer. 117(4):819-25, 2011
    36. Togashi Y, Kim YH, Masago K, Sakamori Y, Okuda C, Mio T, Mishima M.Long-term Survival in a Patient with Small-cell Lung Cancer Undergoing Hemodialysis Who Received Multiple Courses of Chemotherapy. Jpn J Clin Oncol. 41(4):582-5, 2011
    37. Togashi Y, Masago K, Fujita S, Kim YH, Sakamori Y, Hatachi Y, Fukuhara A, Nagai H, Mio T, Mishima M. Association of the transforming growth factor ß1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancer. Oncol Rep. 25(2):377-82, 2011
    38. Masago K, Fujita S, Togashi Y, Irisa K, Sakamori Y, Hatach Yi, Fukuhara A, Nagai H, Kim YH, Mio T, Mishima M. Association between Brain Natriuretic Peptide and the distant metastases of advanced Non-Small Cell Lung Cancer Patients. Oncology Letters. 2: 253-6, 2011
    39. Sakamori Y, Kim YH, Okuda C, Togashi Y, Kinose D, Masago K, Mio T, Uji A, Mishima M.　Two Cases of Cancer-associated Retinopathy Combined with Small-cell Lung Cancer. Jpn J Clin Oncol. 41(5):669-73, 2011
    40. Kim YH, Mishima M. Maintenance chemotherapy for non-small-cell lung cancer. Cancer Treat Rev. 2011 Nov;37(7):505-10.
    41. Togashi Y, Kim YH, Masago K, Tamai K, Sakamori Y, Mio T, Mishima M.Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab. Int J Clin Oncol. 2011 Aug;16(4):444-6.
    42. Togashi Y, Masago K, Fujita S, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Kim YH, Mio T, Mishima M. Differences in Adverse Events between 250 mg Daily Gefitinib and 150 mg Daily Erlotinib in Japanese Patients with Non-small Cell Lung Cancer. Lung Cancer 2011 Oct;74(1):98-102.
    43. Tanaka S, Sakamori Y, Niimi M, Hazama M, Kim YH, Yanagihara K.　Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST).　Trials 2011 May 12;12:120.
    44. Togashi Y, Masago K, Fukudo M, Tsuchido Y, Okuda C, Kim YH, Ikemi Y, Sakamori Y, Mio T, Katsura T, Mishima M. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol. 2011 Oct;68(4):1089-92.
    45. Masago K, Togashi Y, Fukudo M, Terada T, Irisa K, Sakamori Y, Kim YH, Mio T, Inui KI, Mishima M.　Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients with Non-Small-Cell Lung Cancer with Pleural Effusion.　Clin Lung Cancer. 2011 Sep;12(5):307-12.
    46. Masago K, Togashi Y, Fujita S, Sakamori Y, Okuda C, Kim YH, Mio T, Mishima M.　Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.　Med Oncol. 2011 Jul 21.
    47. Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Sakamori Y, Mio T, Mishima M.　Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.　Oncol Rep. 2011 Oct;26(4):795-803.
    48. Kim YH, Mishima M.　How Should We Use Bevacizumab in Patients with Non-small Cell Lung Cancer?　J Thorac Oncol. 2011 Dec;6(12):2145-6.
    49. Kim YH, Fukuhara A, Mishima M.　Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?　Case Rep Oncol. 2011 Sep;4(3):470-4.
        

        2010年度

    50. Fujita K, Kim YH, Yoshino M, Ichikawa M, Mio T, Mishima M. Acute Budd–Chiari syndrome caused by tumor thrombus of the inferior vena cava secondary to non-small cell lung cancer. Respiratory Medicine CME. 3: 26-8, 2010
    51. Kim YH, Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Nishiwaki Y. Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer.　 Respir Med. 104;434-9, 2010
    52. Nagano T, Kim YH, Goto K, Kubota K, Ohmatsu H, Niho S, Yoh K, Naito Y, Saijo N, Nishiwaki Y. Re-challenge chemotherapy for relapsed non-small-cell lung cancer. Lung Cancer. 69(3):315-8, 2010
    53. Togashi Y, Masago K, Fukudo M, Terada T, Ikemi Y, Kim YH, Fujita S, Irisa K, Sakamori Y, Mio T, Inui K, Mishima M. Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis. J Thorac Oncol. 5(5):601-5, 2010
    54. Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, Sakamori Y, Kim YH, Mio T, Inui K, Mishima M. Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer. J Thorac Oncol. 5(7):950-5, 2010
    55. Kim YH, Mishima M, Miyagawa-Hayashino A. Treatment of pulmonary epithelioid hemangioendothelioma with bevacizumab. J Thorac Oncol. 5(7):1107-8, 2010
    56. Kim YH, Masago K, Mishima M. Erlotinib and gastrointestinal ulcer. J Thorac Oncol. 5(7):1108-9, 2010
    57. Kim YH, Mishima M, Yoshizawa A. Gemcitabine-induced acute eosinophilic pneumonia. J Thorac Oncol.5(8):1308-9, 2010
    58. Kim YH, Mio T, Masago K, Irisa K, Sakamori Y, Mishima M. Retrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochloride . Oncology Letters. 1: 569-572, 2010
    59. Kim YH, Mio T, Hamamoto Y, Mishima M. Successful treatment with carboplatin and etoposide in a small-cell lung cancer patient undergoing hemodialysis. Respiratory Medicine CME. 3: 68–70, 2010
    60. Masago K, Togashi Y, Fukudo M, Terada T, Irisa K, Sakamori Y, Fujita S, Kim YH, Mio T, Inui KI, Mishima M. Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation. Case Rep Oncol. 3(2):98-105, 2010
    61. Togashi Y, Kim YH, Miyahara R, Irisa K, Sakamori Y, Masago K, Mio T, Date H, Mishima M.　Octreotide, a somatostatin analogue, in the treatment of chylothorax associated with idiopathic fibrosing mediastinitis.　Tohoku J Exp Med. 222(1):51-3, 2010
    62. Fukuhara A, Masago K, Neo M, Fujibayashi S, Fujita S, Hatachi Y, Irisa K, Sakamori Y, Togashi Y, Kim YH, Mio T, Mishima M. Outcome of Surgical Treatment for Metastatic Vertebra Bone Tumor in Advanced Lung Cancer. Case Rep Oncol. 24;3(1):63-71, 2010
    63. Masago K, Fujita S, Irisa K, Kim YH, Ichikawa M, Mio T, Mishima M. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol. 40(11):1105-9, 2010
    64. Masago K, A Fukuhara, Ito Y, Hatachi Y, Irisa K, Sakamori Y, Togashi Y, Fujita S, Kim YH, Mio T, Mishima M.　Infectious background of febrile advanced lung cancer patients who received chemotherapy. Oncology Letters. 1: 849-53, 2010
    65. Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Sakamori Y, Okuda C, Mio T, Mishima M. Clinical significance of pretreatment C-reactive protein in patients with advanced non-squamous, non-small cell lung cancer who received gefitinib. Oncology. 79(5-6):355-362, 2010
    66. Irisa K, Masago K, Togashi Y, Fujita S, Hatachi Y, Fukuhara A, Sakamori Y, Kim YH, Mio T, Mishima M.　Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor. Med Oncol. 2010 Dec 7.
    67. Fujita S, Masago K, Hatachi Y, Fukuhara A, Hata A, Kaji R, Kim YH, Mio T, Mishima M, Katakami N. Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy. BMC Med Genet. 2010 Nov 30;11:167.
        

        2009年度

    68. Masago K, Fujita S, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Ichikawa M, Mio T, Mishima M.　Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer.　Cancer Sci.　100(10):1917-22, 2009
    69. Kim YH, Mio T, Mishima M. Gefitinib for non-small cell lung cancer patients with liver cirrhosis.　Intern Med. 48(18):1677-9, 2009
    70. Kim YH, Kubota K, Goto K, Yoh K, Niho S, Ohmatsu H, Saijo N, Nishiwaki Y. A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2. Jpn J Clin Oncol. 39(9):576-81, 2009
    71. Kim YH, Ishii G, Goto K, Ota S, Kubota K, Murata Y, Mishima M, Saijo N, Nishiwaki Y, Ochiai A. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.　 Lung Cancer. 65(1):105-11, 2009
    72. Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, Ochiai A. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.　Lung Cancer. 64(1):98-104, 2009
    73. Masago K, Fujita S, Kim YH, Ichikawa M, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Mio T, Mishima M. Epidermal growth factor receptor (EGFR) double-activating somatic mutations in exons 19 and 21 in Japanese non-small cell lung cancer patients. Cancer Genet Cytogenet. 195(2):179-82, 2009